CN110772509A - Imidacloprid and moxidectin diatomic alcohol plastid and preparation method and application thereof - Google Patents
Imidacloprid and moxidectin diatomic alcohol plastid and preparation method and application thereof Download PDFInfo
- Publication number
- CN110772509A CN110772509A CN201910986005.9A CN201910986005A CN110772509A CN 110772509 A CN110772509 A CN 110772509A CN 201910986005 A CN201910986005 A CN 201910986005A CN 110772509 A CN110772509 A CN 110772509A
- Authority
- CN
- China
- Prior art keywords
- parts
- imidacloprid
- moxidectin
- phosphate buffer
- dihydric alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an imidacloprid and moxidectin diatomic alcohol plastid and a preparation method and application thereof, and the insect-repellent preparation comprises the following components: imidacloprid, moxidectin, soybean lecithin, dihydric alcohol (including ethanol and propylene glycol), polysorbate-80 and phosphate buffer. Animal experiments prove that the imidacloprid and moxidectin diatomic alcohol plastid preparation has the effect of resisting in-vivo and in-vitro parasite infection of dogs and cats. Meanwhile, compared with imidacloprid and moxidectin compound transdermal agent, the invention greatly reduces toxicity and has the advantages of good skin permeability, biological slow release, longer action time, better treatment effect and the like.
Description
Technical Field
The invention belongs to the field of insect control, and particularly relates to imidacloprid and moxidectin diatomic alcohol plastid and a preparation method and application thereof.
Background
Pets are human friends, and raising pets has become a leisure way for many families. In recent years, the raising quantity of pets in China is increasing, and the types of pets mainly comprise dogs and cats. As the number of pets increases, a series of problems such as diseases of pets and the like occur. Most of pet diseases are caused by in vivo and in vitro parasitic diseases, and people attract attention. The pet parasites are of various types, wherein the toxocara gondii is an important nematode parasitizing dogs and cats, can cause animal internal organ and eye larva migratory syndrome, and is also a parasitic disease of zoonosis.
The infection rate of ectoparasites such as mites, fleas and lice of dogs and cats is high, which can cause skin itch, depilation, red swelling, scabbing and the like of dogs and cats, and seriously affect the health of pets. In addition, ectoparasites can cause common problems and harm to both humans and animals. In vivo parasites of dogs and cats, such as dog toxocara canis, lion toxocara, dog hookworm, cat toxocara canis, tubular hookworm, and fox hair head nematode, and after infection of dogs and cats, clinical or subclinical symptoms such as diarrhea, malnutrition, growth retardation, and anemia are often caused. The medicine is regularly used for expelling parasites and scientifically feeding, and the immunity is improved, so that the medicine has important significance for the health of people, dogs and cats.
The insect repellent preparation for pets mainly comprises 3 dosage forms: transdermal agents, oral agents and injections are used clinically, and the preparation has the characteristics of simple operation, convenient use and the like, but the treatment effect is not obvious.
Aiming at the existing problems, the research and development of an imidacloprid and moxidectin diatomic alcohol plastid becomes a problem to be solved urgently.
Disclosure of Invention
The invention aims to provide an imidacloprid and moxidectin diatomic alcohol plastid.
Still another object of the present invention is to provide a method for producing the above-described diol plastid.
It is yet another object of the present invention to provide a method for reducing parasites in animals.
Still another object of the present invention is to provide use of the above-mentioned diol plastomer.
The inventor finds that the imidacloprid and moxidectin are compounded in the existing scheme, but the effect of treating the parasites is not obvious, the parasites cannot be completely killed, the action time of the drug is short, and the clinical application has certain limitation.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
in one aspect of the invention, an imidacloprid and moxidectin diatomic ethosome is provided. The dihydric alcohol plastid comprises imidacloprid, moxidectin, soybean lecithin, dihydric alcohol, polysorbate-80 and/or phosphate buffer solution; the dihydric alcohol is ethanol and propylene glycol.
Further, the composition comprises the following components in parts by weight: 5.0-10.0 parts of imidacloprid; 0.5-2.5 parts of moxidectin; 2.0-2.5 parts of soybean lecithin; 30.0-35.0 parts of dihydric alcohol; the dihydric alcohol (ethanol: propylene glycol ═ 7: 3); 0.5-1.0 part of polysorbate-80 and 50-70 parts of phosphate buffer.
Further, the composition comprises the following components in parts by weight: 5.0-9.0 parts of imidacloprid; 0.5-2.0 parts of moxidectin; 2.0-2.4 parts of soybean lecithin; 30.0 to 34.0 parts of dihydric alcohol (ethanol: propylene glycol: 7: 3); 0.5-0.9 part of polysorbate-80; 50-65 parts of phosphate buffer solution.
Further, the composition comprises the following components in parts by weight: 8.0 parts of imidacloprid; 0.5 part of moxidectin; 2.5 parts of soybean lecithin; 32.0 parts of a glycol (ethanol: propylene glycol ═ 7: 3); 0.9 parts of polysorbate-80; 56.5 parts of phosphate buffer.
In another aspect of the invention, a method for preparing imidacloprid and moxidectin diatomic ethosome is provided, which comprises the following steps:
(1) weighing imidacloprid, moxidectin, soybean lecithin, dihydric alcohol (ethanol: propylene glycol 7:3) and polysorbate-80 according to the formula of any one of the above components, stirring under sealed condition until the materials are dissolved, and cooling to room temperature;
(2) dropping phosphate buffer solution, stirring and cooling to room temperature;
(3) obtaining a nanometer ethosome by ultrasonic;
(4) filtering to obtain imidacloprid and moxidectin diatomic alcohol plastid.
Further, the stirring temperature in the step (1) is 29.5-30.5 ℃, and the stirring speed is 600-800 rpm; the dropping speed in the step (2) is 3-6 mL/min; the pH value of the phosphate buffer solution is 6.5-7.0; stirring for 20-30 min.
Further, in the step (3), the ultrasonic power is 100-120W, and the frequency is 45-50 kHz; carrying out ultrasonic treatment for 3-4 s at intervals of 3-4 s for 30-40 cycles; filtering by a 50-100 nm microporous polycarbonate membrane for 10-15 times.
It is yet another object of the present invention to provide a method for reducing parasites in animals. The method for reducing parasites in animals is: applying any one of the above glycol plastids to the dry skin of an animal; the smearing mode is selected from pouring or dipping; the skin is back and neck skin.
The invention also aims to provide the application of the dialcohol plastid in preparing the medicament. The use of the above-mentioned glycol plastid in the preparation of a medicament for the control of animal parasites; the animal is a dog or a cat; the skin is back and neck skin; the parasite population can be reduced by applying the glycol plastid to dry skin of the animal.
Further, the parasite comprises an endoparasite and/or an ectoparasite; the endoparasites include adults, immature adults and L4 stage larvae of Toxobolus canis, Toxobolus angustifolia, Toxobolus felis or Toxobolus tubulosa; the endoparasites include adults of ascaris lion and trichinella foxea; the ectoparasite comprises scabies, fleas or lice.
The imidacloprid has a target of nicotinic acetylcholine receptor, and can block central nerve conduction of parasites and lead the parasites to die by paralysis. The imidacloprid and moxidectin are compounded, so that the infection of parasites inside and outside the bodies of dogs and cats can be effectively prevented. The imidacloprid and moxidectin compound transdermal agent is a main mode of external administration at present, and can achieve the administration effects of slow release, controlled release and targeting by adjusting the imidacloprid and moxidectin compound preparation in order to improve the bioavailability of the medicament.
The invention has the beneficial effects that:
the invention takes imidacloprid and moxidectin as main active ingredients and combines other substances to prepare the ethosome preparation, and the ethosome preparation is beneficial to improving the transdermal depth and the drug retention of epidermis and dermis layers of the active ingredients, prolonging the effective action time of the drugs, prolonging the action time of the preparation and improving the insect expelling effect; greatly reduces the toxicity of the medicine, and has the advantages of good skin permeability, biological slow release, controlled release, safety, no toxic or side effect, longer action time, better treatment effect and the like.
The specific implementation mode is as follows:
in one aspect of the invention, an imidacloprid and moxidectin diatomic ethosome is provided. The dihydric alcohol plastid comprises imidacloprid, moxidectin, soybean lecithin, dihydric alcohol, polysorbate-80 and/or phosphate buffer solution; the dihydric alcohol is ethanol and propylene glycol.
Preferably, the composition comprises the following components in parts by weight: 5.0-10.0 parts of imidacloprid; 0.5-2.5 parts of moxidectin; 2.0-2.5 parts of soybean lecithin; 30.0-35.0 parts of dihydric alcohol; the dihydric alcohol (ethanol: propylene glycol ═ 7: 3); 0.5-1.0 part of polysorbate-80 and 50-70 parts of phosphate buffer.
Preferably, the composition comprises the following components in parts by weight: 5.0-9.0 parts of imidacloprid; 0.5-2.0 parts of moxidectin; 2.0-2.4 parts of soybean lecithin; 30.0 to 34.0 parts of dihydric alcohol (ethanol: propylene glycol: 7: 3); 0.5-0.9 part of polysorbate-80; 50-65 parts of phosphate buffer solution.
Preferably, the composition comprises the following components in parts by weight: 8.0 parts of imidacloprid; 0.5 part of moxidectin; 2.5 parts of soybean lecithin; 32.0 parts of a glycol (ethanol: propylene glycol ═ 7: 3); 0.9 parts of polysorbate-80; 56.5 parts of phosphate buffer.
In another aspect of the invention, a method for preparing imidacloprid and moxidectin diatomic ethosome is provided, which comprises the following steps:
(1) weighing imidacloprid, moxidectin, soybean lecithin, dihydric alcohol (ethanol: propylene glycol 7:3) and polysorbate-80 according to the formula of any one of the above components, stirring under sealed condition until the materials are dissolved, and cooling to room temperature;
(2) dropping phosphate buffer solution, stirring and cooling to room temperature;
(3) obtaining a nanometer ethosome by ultrasonic;
(4) filtering to obtain imidacloprid and moxidectin diatomic alcohol plastid.
Preferably, the stirring temperature in the step (1) is 29.5-30.5 ℃, and the stirring speed is 600-800 rpm; the dropping speed in the step (2) is 3-6 mL/min; the pH value of the phosphate buffer solution is 6.5-7.0; stirring for 20-30 min.
Preferably, the ultrasonic power in the step (3) is 100-120W, and the frequency is 45-50 kHz; carrying out ultrasonic treatment for 3-4 s at intervals of 3-4 s for 30-40 cycles; filtering by a 50-100 nm microporous polycarbonate membrane for 10-15 times.
It is yet another object of the present invention to provide a method for reducing parasites in animals. The method for reducing parasites in animals is: applying any one of the glycol plastids to the dry skin of an animal; the smearing mode is selected from pouring or dipping; the skin is back and neck skin.
The invention also aims to provide the application of the dialcohol plastid in preparing the medicament. The use of any one of the above glycol plastids in the preparation of a medicament for the control of an animal parasite; the animal is a dog or a cat; the skin is back and neck skin; the parasite population can be reduced by applying the glycol plastid to dry skin of the animal.
Preferably, the parasite comprises an endoparasite and/or an ectoparasite; the endoparasites include adults, immature adults and L4 stage larvae of Toxobolus canis, Toxobolus angustifolia, Toxobolus felis or Toxobolus tubulosa; the endoparasites include adults of ascaris lion and trichinella foxea; the ectoparasite comprises scabies, fleas or lice.
The technical solution of the present invention is clearly and completely illustrated below with reference to the following examples, but is not limited thereto.
Example 1
An imidacloprid and moxidectin diatomic ethosome comprises the following components in parts by weight: 5.0 parts of imidacloprid; 1 part of moxidectin; 2.0 parts of soybean lecithin; 30.0 parts of dihydric alcohol (ethanol: propylene glycol ═ 7: 3); polysorbate-80, 0.5 parts and 61.5 parts of phosphate buffer (pH 6.5). (taking a total of 100ml as an example)
A preparation method of imidacloprid and moxidectin diatomic alcohol plastid comprises the following steps:
(1) weighing imidacloprid, moxidectin, soybean lecithin, dihydric alcohol (ethanol: propylene glycol 7:3) and polysorbate-80 according to the proportion, adding into a reaction tank, stirring at 30 ℃ and 700rpm, and stirring until the materials are dissolved;
(2) adding phosphate buffer (pH 6.5) at a dropping rate of 4mL/min, stirring under sealed condition for 20min until completely dissolved, and cooling to room temperature;
(3) performing ultrasonic treatment for 3s at an ultrasonic power of 100W and an ultrasonic frequency of 45kHz at an interval of 3s for 30 cycles, and performing ultrasonic treatment by an ultrasonic pulverizer to obtain a nano ethosome;
(4) filtering with 100nm microporous polycarbonate membrane for 10 times to obtain imidacloprid and Moxidectin dydroxide with uniform distribution and nanometer particle size.
The imidacloprid and moxidectin diatomic alcohol plastid of the invention are characterized in that: the particle size is 45nm, the Zeta potential is-26.31 mV, the drug loading is 36.81 parts, the encapsulation efficiency is 96.05 parts, and the retention of the drug in the dermal layer of the epidermis is 25.14 mu g/cm
2。
Example 2
An imidacloprid and moxidectin diatomic ethosome comprises the following components in parts by weight: 8.0 parts of imidacloprid; 2 parts of moxidectin; 2.5 parts of soybean lecithin; 32.0 parts of dihydric alcohol (ethanol: propylene glycol ═ 7: 3); 0.5 part of polysorbate-80; 55 parts of phosphate buffer (pH 6.5). (taking a total of 100ml as an example)
A preparation method of imidacloprid and moxidectin diatomic alcohol plastid comprises the following steps:
(1) weighing imidacloprid, moxidectin, soybean lecithin, dihydric alcohol (ethanol: propylene glycol 7:3) and polysorbate-80 according to the proportion, adding into a reaction tank, stirring at 30 ℃ and 700rpm, and stirring until the materials are dissolved;
(2) adding phosphate buffer (pH 6.5) at a dropping rate of 4mL/min, stirring under sealed condition for 20min until completely dissolved, and cooling to room temperature;
(3) performing ultrasonic treatment for 3s at an ultrasonic power of 100W and an ultrasonic frequency of 45kHz at an interval of 3s for 30 cycles, and performing ultrasonic treatment by an ultrasonic pulverizer to obtain a nano ethosome;
(4) filtering with 100nm microporous polycarbonate membrane for 10 times to obtain imidacloprid and Moxidectin dydroxide with uniform distribution and nanometer particle size.
The preparation of imidacloprid and moxidectin diatomic alcohol plastid prepared by the invention is characterized in that: the particle size is 42nm, the Zeta potential is-27.01 mV, the drug loading rate is 37.11 parts, the encapsulation rate is 97.34 parts, and the retention of the drug in the dermal layer of the epidermis is 26.31 mu g/cm
2。
Example 3
An imidacloprid and moxidectin diatomic ethosome comprises the following components in parts by weight: 10.0 parts of imidacloprid; 2.5 parts of moxidectin; 2.5 parts of soybean lecithin; 35.0 parts of dihydric alcohol (ethanol: propylene glycol ═ 7: 3); 0.5 part of polysorbate-80; 49.5 parts of phosphate buffer (pH 6.5). (taking a total of 100ml as an example)
A preparation method of imidacloprid and moxidectin diatomic alcohol plastid comprises the following steps:
(1) weighing imidacloprid, moxidectin, soybean lecithin, dihydric alcohol (ethanol: propylene glycol 7:3) and polysorbate-80 according to the proportion, adding into a reaction tank, stirring at 30 ℃ and 700rpm, and stirring until the materials are dissolved;
(2) adding phosphate buffer (pH 6.5) at a dropping rate of 4mL/min, stirring under sealed condition for 20min until completely dissolved, and cooling to room temperature;
(3) performing ultrasonic treatment for 3s at an ultrasonic power of 100W and an ultrasonic frequency of 45kHz at an interval of 3s for 30 cycles, and performing ultrasonic treatment by an ultrasonic pulverizer to obtain a nano ethosome;
(4) filtering with 100nm microporous polycarbonate membrane for 10 times to obtain imidacloprid and Moxidectin dydroxide with uniform distribution and nanometer particle size.
The invention has the following pharmaceutical characteristics: the particle size is 41nm, the Zeta potential is-27.64 mV, the drug loading rate is 37.53 parts, the encapsulation rate is 97.47 parts, and the retention of the drug in the dermal layer of the epidermis is 27.41 mu g/cm
2。
Example 4
An imidacloprid and moxidectin diatomic ethosome comprises the following components in parts by weight: 8.0 parts of imidacloprid; 2 parts of moxidectin; 2.5 parts of soybean lecithin; 32.0 parts of dihydric alcohol (ethanol: propylene glycol ═ 7: 3); polysorbate-80, 1.0 part; 55 parts of phosphate buffer (pH 6.5). (taking a total of 100ml as an example)
A preparation method of imidacloprid and moxidectin diatomic alcohol plastid comprises the following steps:
(1) weighing imidacloprid, moxidectin, soybean lecithin, dihydric alcohol (ethanol: propylene glycol 7:3) and polysorbate-80 according to the proportion, adding into a reaction tank, stirring at 29.5 ℃ and 600rpm until the materials are dissolved;
(2) then adding phosphate buffer (pH 6.5) at a dropping rate of 3mL/min, stirring under sealed condition for 30min until completely dissolving, and cooling to room temperature;
(3) performing ultrasonic treatment for 4s at an ultrasonic power of 120W and an ultrasonic frequency of 50kHz at an interval of 4s for 40 cycles, and performing ultrasonic treatment by an ultrasonic pulverizer to obtain a nano ethosome;
(4) filtering with 50nm microporous polycarbonate membrane for 15 times to obtain imidacloprid and Moxidectin dydroxide with uniform distribution and nanometer particle size.
The preparation of imidacloprid and moxidectin diatomic alcohol plastid prepared by the invention is characterized in that: the particle size is 42nm, the Zeta potential is-27.01 mV, the drug loading rate is 37.11 parts, the encapsulation rate is 97.34 parts, and the retention of the drug in the dermal layer of the epidermis is 26.31 mu g/cm
2。
Example 5
An imidacloprid and moxidectin diatomic ethosome comprises the following components in parts by weight: 8.0 parts of imidacloprid; 0.5 part of moxidectin; 2.5 parts of soybean lecithin; 32.0 parts of dihydric alcohol (ethanol: propylene glycol ═ 7: 3); 0.9 part of polysorbate-80; 56.5 parts of phosphate buffer (pH 6.5). (taking a total of 100ml as an example)
A preparation method of imidacloprid and moxidectin diatomic alcohol plastid comprises the following steps:
(1) weighing imidacloprid, moxidectin, soybean lecithin, dihydric alcohol (ethanol: propylene glycol 7:3) and polysorbate-80 according to the proportion, adding into a reaction tank, stirring at 30.5 ℃ and 800rpm at a stirring speed until the materials are dissolved;
(2) adding phosphate buffer (pH 6.5) at a dropping rate of 6mL/min, stirring under sealed condition for 25min until completely dissolved, and cooling to room temperature;
(3) performing ultrasonic treatment for 3s at an ultrasonic power of 100W and an ultrasonic frequency of 45kHz at an interval of 3s for 30 cycles, and performing ultrasonic treatment by an ultrasonic pulverizer to obtain a nano ethosome;
(4) filtering with 100nm microporous polycarbonate membrane for 12 times to obtain imidacloprid and Moxidectin dydroxide with uniform distribution and nanometer particle size.
The preparation of imidacloprid and moxidectin diatomic alcohol plastid prepared by the invention is characterized in that: the particle size is 42nm, the Zeta potential is-27.01 mV, the drug loading rate is 37.11 parts, the encapsulation rate is 97.34 parts, and the retention of the drug in the dermal layer of the epidermis is 26.31 mu g/cm
2。
Comparative example 1
Imidacloprid and moxidectin compounded transdermal agent, which comprises 10 parts of imidacloprid; 2.5 parts of moxidectin; 5 parts of isopropanol; 82.5 parts of ethanol.
The antiparasitic effect of imidacloprid and moxidectin dialkoxide prepared by the invention is illustrated by combining specific experiments.
Experimental materials:
control drugs: imidacloprid and moxidectin compound transdermal agent.
Imidacloprid, moxidectin diatomic alcohol plastid: inventive example formulations.
Experimental animals: 50 affected dogs veterinarily diagnosed with ectoparasites were provided by a canine farm.
50 diseased cats with ectoparasites diagnosed by a veterinarian were provided by the cat farm.
The experimental method comprises the following steps:
grouping: the 50 sick dogs were randomly divided into 7 groups, which were experimental group 1-5, drug control group and blank control group, respectively.
The 50 diseased cats were randomly divided into 7 groups, which were experimental 8-12, drug control and blank control groups, respectively.
And (3) treatment: groups 1-6, administered at a dose of 0.1ml per 1Kg body weight, dropped between scapulae on the back of a dog, administered 1 time, and the healing condition was observed. (the glycol plastid is applied to the dry neck or back skin of the animal by pouring or dipping)
The control dogs were not dosed and observed for onset of disease.
Groups 8-13, administered 0.1ml per 1Kg body weight, dropped between scapulae on back of cat, administered 1 time, and the cure condition was observed. The control cats were not medicated and were observed for disease onset.
The test lasted 1 month, and the test groups are shown in table 1.
TABLE 1 test grouping
Scraping skin tissues at the junction of a diseased part and healthy skin on days 1, 2, 7, 14, 21, 28, 35, 42, 49, 56 and 63 after application, placing the skin tissues in a culture dish, and inspecting the conditions of worms, mites, fleas, lice and ova by a humidifying method.
Collecting fecal samples on days 1, 2, 7, 14, 21, 28, 35, 42, 49, 56 and 63 after administration, and detecting the excretion of roundworm and hookworm eggs. The reduction rate was calculated according to the following formula.
Evaluation of results, cure: clinical symptoms disappear, and the insect reduction rate is more than 80 parts; the method has the following advantages: the disease condition is obviously improved, and 80 parts of the pesticide composition is more than or equal to 60 parts of the pest reduction rate; and (4) invalidation: the disease condition is not obviously improved or aggravated, and the insect reduction rate is less than 60 parts.
Reduction rate (in parts) is (average number of adults detected in control group-average number of adults detected in experimental group)/(average number of adults detected in control group)
The experimental results are as follows: the relevant clinical symptoms of the experimental animals were observed and recorded daily. 2 days after the administration, the symptoms of ectoparasite infection were reduced in groups 1 to 6 and 8 to 13 to which the preparations of examples were added, and the crust portion fell off. After 7 days of administration, the symptoms of ectoparasite infection completely disappeared in groups 1-6 and 8-13, and the number of parasites was significantly reduced to zero when no helminths, fleas and eggs were detected in microscopic examination.
The treatment effect of each drug group except the control group was still effective 42 days after the administration, wherein the treatment effect of example groups 1 to 5 for dogs and example groups 8 to 12 for cats was superior to that of control group 6 for drug dogs and control group 13 for drug cats, respectively.
In addition, the treatment effect of the groups 1 to 5 and the groups 8 to 12 can be maintained for 63 days after the administration, while the treatment effect of the imidacloprid and moxidectin compound transdermal agent of the drug control group can be maintained for 42 days after the administration. There was no improvement in symptoms in control 7 and control 14. The specific experimental results are shown in table 2.
TABLE 2 clinical efficacy of groups on ectoparasites of experimental animals
In conclusion, the imidacloprid and moxidectin dialogues of the present invention can control/kill (i.e., the number of parasites is significantly reduced or even zero) endoparasites and ectoparasites. Endoparasites include adult, immature adult and L4 stage larvae of Carposina canis, Carposina canis and Leptodermia stricta, adult of Carposina lion and Carposina hirta; adult, immature adult and L4 stage larvae of Toxobolus catus and Toxomatoda; ectoparasites, including scabies, fleas, or lice.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (10)
1. A dialcohol plastid, which is characterized by comprising imidacloprid, moxidectin, soybean lecithin, dihydric alcohol, polysorbate-80 and/or phosphate buffer; the dihydric alcohol is ethanol and propylene glycol.
2. The dialiposome of claim 1, wherein the dialiposome comprises the following components in parts by weight: 5.0-10.0 parts of imidacloprid; 0.5-2.5 parts of moxidectin; 2.0-2.5 parts of soybean lecithin; 30.0-35.0 parts of dihydric alcohol; 0.5-1.0 part of polysorbate-80 and 50-70 parts of phosphate buffer; the dihydric alcohol comprises ethanol and propylene glycol.
3. The dialiposome of claim 2, wherein the dialiposome comprises the following components in parts by weight: 5.0-9.0 parts of imidacloprid; 0.5-2.0 parts of moxidectin; 2.0-2.4 parts of soybean lecithin; 30.0-34.0 parts of dihydric alcohol; 0.5-0.9 part of polysorbate-80; 50-65 parts of phosphate buffer solution.
4. The dialiposome of claim 3, wherein the dialiposome comprises the following components in parts by weight: 8.0 parts of imidacloprid; 0.5 part of moxidectin; 2.5 parts of soybean lecithin; 32.0 parts of dihydric alcohol; 0.9 parts of polysorbate-80; 56.5 parts of phosphate buffer.
5. The method for producing a dialiposome according to any one of claims 1 to 4, comprising the steps of:
(1) weighing imidacloprid, moxidectin, soybean lecithin, dihydric alcohol and polysorbate-80 according to the formula of any one of claims 1 to 4, stirring in a closed manner until the materials are dissolved, and cooling to room temperature;
(2) dropping phosphate buffer solution, stirring and cooling to room temperature;
(3) obtaining a nanometer ethosome by ultrasonic;
(4) filtering to obtain imidacloprid and moxidectin diatomic alcohol plastid.
6. The preparation method according to claim 5, wherein the stirring temperature in the step (1) is 29.5 to 30.5 ℃, and the stirring speed is 600 to 800 rpm; the dropping speed in the step (2) is 3-6 mL/min; the pH value of the phosphate buffer solution is 6.5-7.0; stirring for 20-30 min.
7. The preparation method according to claim 5, wherein the ultrasonic power in the step (3) is 100-120W, and the frequency is 45-50 kHz; carrying out ultrasonic treatment for 3-4 s at intervals of 3-4 s for 30-40 cycles; filtering by a 50-100 nm microporous polycarbonate membrane for 10-15 times.
8. A method for reducing parasites on animals, comprising applying the diol plastomer of any one of claims 1 to 4 to the dry skin of an animal; the smearing mode is selected from pouring or dipping; the skin is back and neck skin.
9. Use of a dialiposome according to any one of claims 1 to 4 for the preparation of a medicament for controlling parasites in animals; the animal is a dog or a cat; the skin is back and neck skin; the parasite population can be reduced by applying the glycol plastid to dry skin of the animal.
10. Use according to claim 9, wherein the parasites comprise endoparasites and/or ectoparasites; the endoparasites include adults, immature adults or L4 stage larvae of Toxobolus canis, Toxomatoda canis, 1 gibbos angustifolia, Toxobolus felis or Toxomatoda tubulosa; the endoparasites include adults of ascaris lion and trichinella foxea; the ectoparasite comprises scabies, fleas or lice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910986005.9A CN110772509A (en) | 2019-10-17 | 2019-10-17 | Imidacloprid and moxidectin diatomic alcohol plastid and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910986005.9A CN110772509A (en) | 2019-10-17 | 2019-10-17 | Imidacloprid and moxidectin diatomic alcohol plastid and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110772509A true CN110772509A (en) | 2020-02-11 |
Family
ID=69385757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910986005.9A Pending CN110772509A (en) | 2019-10-17 | 2019-10-17 | Imidacloprid and moxidectin diatomic alcohol plastid and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110772509A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114259464A (en) * | 2021-11-25 | 2022-04-01 | 吉林大学 | Compound moxidectin external drop |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101273971A (en) * | 2008-05-09 | 2008-10-01 | 绍兴文理学院 | Ethosomes preparation of antimycotics pharmaceutical and method for preparing the same |
| CN103462883A (en) * | 2013-09-06 | 2013-12-25 | 武汉理工大学 | Matrine diatomic alcohol plastid temperature-sensitive gel and preparation method thereof |
| US20150237849A1 (en) * | 2012-06-22 | 2015-08-27 | Smartvet Pty Ltd. | Dosage Regime for Animal Treatment |
| CN106511267A (en) * | 2017-01-18 | 2017-03-22 | 佛山市南海东方澳龙制药有限公司 | Compound moxidectin drops as well as preparation method and application thereof |
| CN108883092A (en) * | 2016-05-18 | 2018-11-23 | 拉柏斯美国有限责任公司 | The ectoparasite disease of dog and the animal medicinal composition comprising imidacloprid, Moxidectin and praziquantel for skin surface application (spray drop) of internal parasitic disease are influenced for treating and preventing |
-
2019
- 2019-10-17 CN CN201910986005.9A patent/CN110772509A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101273971A (en) * | 2008-05-09 | 2008-10-01 | 绍兴文理学院 | Ethosomes preparation of antimycotics pharmaceutical and method for preparing the same |
| US20150237849A1 (en) * | 2012-06-22 | 2015-08-27 | Smartvet Pty Ltd. | Dosage Regime for Animal Treatment |
| CN103462883A (en) * | 2013-09-06 | 2013-12-25 | 武汉理工大学 | Matrine diatomic alcohol plastid temperature-sensitive gel and preparation method thereof |
| CN108883092A (en) * | 2016-05-18 | 2018-11-23 | 拉柏斯美国有限责任公司 | The ectoparasite disease of dog and the animal medicinal composition comprising imidacloprid, Moxidectin and praziquantel for skin surface application (spray drop) of internal parasitic disease are influenced for treating and preventing |
| US20190070158A1 (en) * | 2016-05-18 | 2019-03-07 | Labyes Usa, Llc | Veterinary composition comprising imidacloprid, moxidectin and praziquantel for cutaneous topical application (spot on), for the treatment and prevention of ecto and endoparasitoses affecting dogs |
| CN106511267A (en) * | 2017-01-18 | 2017-03-22 | 佛山市南海东方澳龙制药有限公司 | Compound moxidectin drops as well as preparation method and application thereof |
Non-Patent Citations (6)
| Title |
|---|
| 何一鸣等: "盐酸特比萘芬二元醇质体的制备及体外评价", 《广东药学院学报》 * |
| 元晓琪等: "犬猫驱虫滴剂浅述", 《中国畜牧兽医文摘》 * |
| 刘园园等: "醇质体在经皮给药系统中的应用研究", 《中国药房》 * |
| 李艳艳等: "犬猫常见寄生虫病及防治药物", 《四川畜牧兽医》 * |
| 邢文善等: "酮洛芬药剂学研究进展", 《中国合理用药探索》 * |
| 静静: "爱沃克 爱护你我它", 《宠物世界(狗迷)》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114259464A (en) * | 2021-11-25 | 2022-04-01 | 吉林大学 | Compound moxidectin external drop |
| CN114259464B (en) * | 2021-11-25 | 2022-11-22 | 吉林大学 | Compound moxidectin external drop |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105616406B (en) | Topical localized isoxazoline formulations | |
| JP2018154657A (en) | Endermic topical isoxazoline formulation containing glycofurol | |
| EP3195857A1 (en) | Use of a trp modulator for the prophylaxis and/or alleviating of grass tetany and/or parturient paresis in tylopoda or ruminants | |
| CN105853454A (en) | Broad-spectrum antiparasitic drug nano-emulsion and preparation method thereof | |
| CN109568249A (en) | A kind of women secret maintenance bacteriostatic gel and its preparation method and application | |
| CN114259464B (en) | Compound moxidectin external drop | |
| BG107038A (en) | Composition against endopa gel | |
| CN106511267A (en) | Compound moxidectin drops as well as preparation method and application thereof | |
| PT1957040E (en) | Benzimidazole non-aqueous compositions | |
| CN110772509A (en) | Imidacloprid and moxidectin diatomic alcohol plastid and preparation method and application thereof | |
| US10952988B2 (en) | Methods for controlling the spread of dirofilariosis | |
| CN110664806B (en) | Fipronil and methoprene dihydric alcohol plastid and preparation method and application thereof | |
| CN111514157A (en) | Application of composition in preparation of veterinary anti-parasitic drug, veterinary anti-parasitic transdermal solution and preparation method thereof | |
| JPH06211792A (en) | Systemic extermination of parasite | |
| CN110721152B (en) | Sustained-release composition for treating animal skin parasite and fungus infection | |
| CN107157995A (en) | A kind of compound imidacloprid transdermal composition preparation of pet broad-spectrum anti-parasite | |
| CN110680803A (en) | Selamectin ethosome preparation and preparation method and application thereof | |
| RU2709535C1 (en) | Method for preventing and treating parasitic diseases of farm animals and birds | |
| AU2015101787A4 (en) | Antiparasitic formulations for oral administration | |
| Kotb et al. | Epidemiological studies of equine mange with special reference to different therapeutic protocols for effective treatment of Chorioptic mange | |
| Barron | Appendix II Formulary for Common Wildlife Species | |
| CN112294831B (en) | Transdermal drop for expelling parasites on animals and preparation method thereof | |
| Prokulewicz et al. | Evaluation of the efficacy of doramectin in the control of strongyle (Strongylidae, Cyathostominae) infestation in horses. | |
| CN115317498B (en) | Compound drop for treating canine and feline parasites and fungal skin diseases and preparation method thereof | |
| CN111568886B (en) | Chinese and western medicine compound film coating agent for treating bovine acariasis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200211 |
|
| RJ01 | Rejection of invention patent application after publication |